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Abstract
Background:  Desmuslin is an α -dystrobrevin-interacting protein expressed primarily in heart and
skeletal muscle. The desmuslin protein interacts with and is closely related to desmin, a protein
encoded by a locus mutated in some forms of hereditary distal myopathy. As a muscle-specific
intermediate filament protein, desmuslin is also a candidate for myopathies of unknown etiology.
Results:  The desmuslin gene was localized to chromosome 15q26.3 by electronic screening of the
human DNA sequence database. Primer pairs were designed to amplify the 5 exons of the
desmuslin gene in 11 overlapping DNA segments. The desmuslin gene was screened for mutations
in 71 patients with various forms of myopathy for which there was no known cause. In this analysis,
10 common and 2 rare amino acid altering single-nucleotide polymorphisms were identified, all of
which were seen in a control population of individuals thus making these unlikely causes of the
phenotype. Interestingly, one of the single-nucleotide polymorphisms found in a patient resulted in
a premature stop codon in the first exon. The nonsense mutation was also detected in the patient's
unaffected father and one unaffected control; it was detected in 0.44% (2/454) of unrelated
chromosomes and is therefore predicted to have a homozygous frequency of 0.002%.
Conclusion:  No causative mutations were found in the desmuslin gene. However, the single-
nucleotide polymorphisms mapped in this study represent a well-mapped group that can be used
for disequilibrium studies of this region of chromosome 15q26.3.
Background
Dystrophin and its associated proteins are thought to be
involved in the anchoring of the muscle cell membrane to
the extracellular matrix [1], and the absence of many of
these proteins can lead to the phenotype of muscular
dystrophy [2]. The dystrophin-associated protein com-
plex (DAPC) consists of several subgroups of protein
complexes, each associated either directly or indirectly
with dystrophin. The sarcoglycans are four transmem-
brane proteins [3] that are organized by a fifth protein
called sarcospan [4]. This complex is thought to be in-
volved in signalling at the cell membrane [5]. A second
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subcomplex, known as the dystroglycan complex [6], in-
teracts directly with dystrophin in the cytoplasm and
laminin in the extracellular matrix, thus providing a
structural link between the inside and the outside of the
cell. A third subcomplex involves the dystrobrevins [7, 8]
and syntrophins [9] which form a complex at the C-ter-
minal region of dystrophin [10,11,12] and have an as yet
unidentified function.
Desmuslin (DMN) was recently identified as an α -dys-
trobrevin-interacting protein via the yeast two-hybrid
method [13]. Both desmuslin mRNA and protein are ex-
pressed primarily in cardiac and skeletal muscle and the
gene encodes a novel intermediate filament (IF) protein
of 1253 amino acids. Electron microscopic analysis
shows that desmuslin colocalizes with desmin, another
muscle IF protein. Co-immunopreciptation experiments
revealed that the desmuslin and α -dystrobrevin interac-
tion involves the region of protein encoded by exons 8-16
of α -dystrobrevin and domains 1A through 2A of the des-
muslin rod domain. Desmuslin is hypothesized to func-
tion as a mechanical support to the muscle myofibers by
making a previously unrecognized linkage between the
extracellular matrix via the DAPC and the Z-discs
through desmin and plectin [14].
As several IF proteins, including desmin, have been im-
plicated in human genetic disorders such as dominant
and recessive congenital and adult onset myopathies
[15,16,17,18], desmuslin becomes a candidate to be in-
volved in myopathies as well. Supporting this is the ex-
clusive expression of DMN in skeletal and cardiac
muscle. The DMN gene was analyzed for mutations in 71
patients with various forms of muscular dystrophy and
myopathy. In addition to 9 single-nucleotide polymor-
phisms (SNPs) that do not change the protein sequence,
we identified 12 SNPs that do alter the residue they en-
code. Although examination of controls has shown that
none of them is likely to cause the phenotype, our results
are useful for future disequilibrium studies of this region
of chromosome 15q26.3 and for mutation analysis and
association studies in other genetic disorders.
Results and Discussion
Using the DMN cDNA sequence (AF359284) as a query
to blast the public human genome database, we found a
genomic clone (AC018999) that included the entire des-
muslin coding sequence. The alignment identified 5 ex-
ons which are schematically indicated in Figure 1. Eleven
sets of primer pairs were developed to amplify the 5 ex-
ons and the flanking intron sequences (Table 1). The
primers were designed to amplify overlapping segments
of the desmuslin coding sequence as indicated in Figure
1.
Desmin, a desmuslin-interacting protein, has been im-
plicated in hereditary distal myopathies implying that
desmuslin itself may also be involved in myopathies of
unknown etiology. DNA samples isolated from 71 dys-
trophic and myopathic patients (as described in Table 2)
Table 1: Eleven PCR primer sets that allow the amplification of 
the entire coding sequence and surrounding intronic sequence of 
the DMN gene.
Primer Primer Sequence
1F 5' - ATCCACCAAGGCCAGGACACTCGTATGCTCC
1R 5' - TCGTCCTCGTACAGCTGCAC
2F 5' - GGAGAGGACGAGACCGGGACAAGACCA
2R 5' - CGGAAATGCATGGTAAGGCTG
3F 5' - GAGCTGCAGCGCCTGGATGCGGAGGAG
3R 5' - GTTAAAGCAGCTGCCACCTAACCCCATGAC-
GAGGA
4F 5' - GGAAACCATCCTGCAAGTGACTGCATG
4R 5' - GAGACACCTGCTCAGTGACCTAAGC
5F 5' - GGTGACACTATGGTCATTGGCCGCATACCAC
5R 5' - CCAGGGGTGTGAAACACAAGTTCAGGTGCAC
6F 5' - CACAAAAACGAGCACCTCTGACCTCTCTGGG
6R 5' - GAATGACGGTCCTCTCATTTGACCG
7F 5' - CCAACGTCAGAACTTTCTCTCCAACC
7R 5' - CCAGGCCAGCTTCATCGGAAACATC
8F 5' - GTCACTTACGTGGACAGGAAAGAGC
8R 5' - GACTGTGGGTTCGGCATGAAATTC
9F 5' - GGGCGAGCAGAGTTATTTTGTGTCC
9R 5' - CTCCATCTCACTGGCCTCATCTTTGC
10F 5' - GAGCGTTTCCGTGGATGTCAAGAAG
10R 5' - GATGACTTCTCTGGACAGTGGACTTTGACCGG
11F 5' - GAGCGTTTCCGTGGATGTCAAGAAG
11R 5' - GTTAAGGCCTTTGGATGTTGGCACG
Table 2: Summary of clinical diagnoses and pathological findings 
of patient samples studied for alterations in DMN.
Clinical Diagnosis Description # of samples
Congenital Myopathy Nemaline Myopathy 50
Multicore/minicore Disease 6
Myotubular Myopathy 2
Spheroid Body Myopathy 1
Desmuslin accumulation 2
Undefined 2
Muscular Dystrophy Limb-Girdle MD 4
Undefined 4BMC Genetics (2001) 2:8 http://www.biomedcentral.com/1471-2156/2/8
were analyzed by direct sequencing to determine wheth-
er the phenotype was the result of a desmuslin mutation.
All observed variants were subsequently tested in ≤  156
control individuals. These analyses revealed 10 common
and 2 rare SNPs [19, 20] that alter an amino acid codon;
7 result in non-conservative amino acids changes (Table
3).
None of the SNPs seem associated with the patient phe-
notypes as each was also found in the control population.
Nine silent SNPs, which did not alter an amino acid, were
also identified in the patient population; several of these
SNPs showed a high degree of heterozygosity. Most were
tested for and detected in the control population, thus
making desmuslin an unlikely candidate to be involved
in these myopathies, but this first pass can be followed by
others in a larger set of patient samples.
Interestingly, SNP 3, a C598T substitution resulting in a
premature stop codon in exon 1, was detected in a single
Nemaline myopathy patient. Neither the proband's
mother nor any of the other patients was found to carry
this mutation (Figure 2A). The C598T mutation removed
a Pvu II site, thus permitting detection of the alteration
by restriction digest analysis of a PCR product generated
from genomic DNA. The assay is outlined schematically
in Figure 2B and documented in Figure 2C. Using this
Pvu II assay, the C598T change was detected in the unaf-
fected father of the patient, making it unlikely that heter-
ozygosity for the C598T change is the causative mutation
in the myopathic proband.
The removal of the Pvu II site allowed rapid screening of
additional patients and control samples by DNA amplifi-
cation of the region and subsequent digestion of the PCR
product with Pvu II. One of 312 control chromosomes
was found to have lost the Pvu II site, and the hetero-
zygous presence of the C598T mutation was confirmed
by DNA sequencing of the PCR product. Thus it is likely
that the C598T mutation is not responsible for the myo-
pathic phenotype of the proband. This is a surprising re-
sult considering that a single copy of this stop codon is
present in 0.44% (2/454) of the population and 0.002%
of the population is predicted to carry this nonsense mu-
tation in a homozygous state. The phenotype of the latter
individuals is not known.
There is the possibility that either the heterozygous
C598T DMN mutation combined with another mutation
in a different gene or the C598T in a homozygous state
causes muscular dystrophy or myopathy of unknown ge-
netic pathogenesis. The C598T DMN mutation is a good
candidate to be a modifier for muscular and/or cardiac
phenotypes, considering: (i) the frequency of the muta-
tion in the normal population in the heterozygous as well
as homozygous state; and (ii) the key role of desmuslin in
connecting the Z-discs to the extracellular matrix. The
desmuslin SNPs should be examined in a larger set of
Figure 1
Schematic representation of the desmuslin gene and protein. Desmuslin protein structure, genomic organization,
approximate location of SNPs identified in this study and primer pairs used to amplify the entire coding sequence are indicated.
A comparison of the DMN cDNA sequence with its related genomic DNA led to the identification of 5 exons ranging from 71
bp (exon 3) to 2447 bp (exon 4). The exact start of transcription in exon 1 and the termination of transcription at the end of
exon 5 are unknown. Unlike the brain DMN cDNA, muscle DMN cDNA does not contain the sequence between exons 4 and
5 (indicated by an open box). The locations of the 21 SNPs are indicated by arrows; the 12 SNPs that alter an amino acid
codon are shown in red and the 9 silent SNPs are shown in black. The exact position of each of the SNPs is described in Table
3. The positions of the 11 primer pairs are also shown below the respective exons.
125 bp 71 bp 2447 bp
811 935 936 1006 1007 3453
309 bp
3454
TAA
3762 bp
810 bp
GT
1 810
ATG
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5
GT GT GT AG AG AG AG
2F 2R 4F 4R 5F 5R 7R 7F
3F 3R 8F 8R
9F 9R
10F 10R
1F 1R 6F 6R 11F 11R
C-terminal domain Rod domain
N-terminal domain
Protein
Gene
SNP
Primers
BrainBMC Genetics (2001) 2:8 http://www.biomedcentral.com/1471-2156/2/8
Figure 2
Analysis of SNP3 (C598T) in patient and control samples. (A) Sequence results of the C598T patient and his mother.
At nucleotide number 598, the patient has a C and T, indicated by N. The patient's unaffected mother is homozygous for C. (B)
Pvu II site amplified with 3F and 3R. The size of PCR product amplified with 3F and 3R is 790 bp and contains three Pvu II
restriction sites. When the PCR product from a control subject is digested with Pvu II, four products of 321 bp, two of 138 bp
and two of 10 bp are generated. Since the C598T removes the first Pvu II restriction site, digestion of the amplification product
will produce a fragment of 459 bp instead of 321 bp and 138 bp. (C) Electrophoresis of PCR product digested with Pvu II
shows that the patient and his unaffected father both have a band of 459 bp. The 138 bp fragment in the mother and control is
twice as strong as those of the patient and the father. Similarly the 321 bp band in the mother and control is stronger than in
the patient and his father.
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myopathy and muscular dystrophy patients to test this
hypothesis. More specifically, it should be determined
whether there is a statistically significant difference in
the frequency of individual or clustered SNP haplotypes
between the patient and the control populations.
The desmuslin coding sequence is highly polymorphic
with 9 SNPs that do not alter an amino acid and 12 that
do. Ten of these variations have minor allele frequencies
that are represented in over 10% of the chromosomes
sampled. These 10 are spaced within a genomic interval
of ≤  28 kilobases, or approximately 1 per 2800 bases.
These highly informative markers are thus very useful
for genetic analysis. The presence of so many SNPs with-
in the coding sequence of a protein is somewhat unex-
pected and is much greater than that documented for
other genes. This degree of variability may reflect a re-
dundancy of desmuslin at the Z-line where other IF pro-
teins with potentially overlapping functions are located
[21].
Table 3: Summary of SNPs in theDMN gene.
Nucleotide Nucleotide Amino 
Acid
# of chromosomes
SNP Exon Domain Position Change Position Amino Acid Change Total %
1 1 Rod 408 CGG 136 none 91 64.1
CGA 51 35.9
2 1 Rod 457 AGG 153 none 91 64.1
CGG 51 35.9
3 1 Rod 598 CAG 200 Gln non-conservative 452 99.6
TAG STOP 2 0.4
4 2 Rod 815 GCG 272 Ala conservative 103 57.9
GTG Val 75 42.1
5 3 C-terminal 988 GTT 330 Val conservative 165 90.7
ATT Ile 17 9.3
6 4 C-terminal 1063 AGG 335 Arg non-conservative 79 87.8
TGG Trp 11 12.2
7 4 C-terminal 1596 TCC 532 none 128 91.4
TCT 12 8.6
8 4 C-terminal 1700 CCG 567 Pro conservative 149 81.9
CTG Leu 33 18.1
9 4 C-terminal 1713 AGC 571 none 162 89.0
AGT 20 11.0
10 4 C-terminal 1835 GAA 612 Glu non-conservative 180 97.8
GCA Ala 4 2.2
11 4 C-terminal 1953 ACT 651 none 131 72.8
ACC 49 27.2BMC Genetics (2001) 2:8 http://www.biomedcentral.com/1471-2156/2/8
Conclusions
The characterization of the individual components that
form protein complexes in skeletal muscle and heart, es-
pecially information concerning genotype-phenotype
correlations, will increase our understanding of the
pathophysiology of human muscle diseases. We encour-
age other groups to test for the presence of the C598T
DMN mutation in their human patient samples affected
by muscular and cardiac diseases. The generation of des-
muslin null animal models will also contribute to the un-
derstanding of the role of this protein in muscle and
cardiac disease.
Materials and Methods
Blood samples were obtained from patients and control
subjects under IRB-approved informed consent. The ge-
nomic DNA extracted from these blood samples was
used as the template for the PCR assay. Using an Advan-
12 4 C-terminal 2010 TAC 670 none 176 97.8
TAT 42 . 2
13 4 C-terminal 2282 CCG 761 Pro conservative 114 91.9
CTG Leu 10 8.1
14 4 C-terminal 2424 CCC 808 none 63 75.0
CCT 21 25.0
15 4 C-terminal 2836 CGG 946 Arg non-conservative 324 99.4
TGG Trp 2 0.6
16 4 C-terminal 2927 CAG 976 Gln non-conservative 187 98.4
CGGA r g 3 1 . 6
17 4 C-terminal 2937 CCG 979 none 187 99.5
CCA 10 . 5
18 4 C-terminal 3176 CCG 1059 Pro conservative 126 98.4
CTGL e u 2 1 . 6
19 4 C-terminal 3195 TTC 1065 none 95 76.6
TTT 29 23.4
20 4 C-terminal 3200 CGT 1067 Arg non-conservative 114 91.9
CCT Pro 10 8.1
21 4 C-terminal 3230 TCA 1077 Ser non-conservative 115 89.8
TTA Leu 13 10.2
The details of 21 SNPs are shown. The exon and domain location as well as the nucleotide and amino acid positions of SNP are given. Also listed are 
the major and minor alleles, both as nucleotide and amino acid, and the corresponding frequencies, in terms of numbers of chromosomes and per-
centage. The nucleotide substitution is highlighted in bold. The amino acid change indicates the degree of alteration in the encoded residue; the change 
is described as none if there was no change, conservative if the alteration does not change the residue's polarity or charge, and non-conservative if 
the polarity and/or charge of the encoded residues differ.
Table 3: Summary of SNPs in theDMN gene. (Continued)BMC Genetics (2001) 2:8 http://www.biomedcentral.com/1471-2156/2/8
tage-GC cDNA PCR polymerase (Clontech) and Pfu DNA
polymerase (Stratagene), PCR was carried out with
primers specific to the exon and/or intron of DMN se-
quence (Table 1) under the following conditions: 94°C
for 1 min followed by 35 cycles of 94°C for 1 min, 57-59
°C for 1 min, 72°C for 3 min and a final extension time of
10 min at 72°C. The amplification products were purified
using the QIAGEN PCR purification kit and analyzed on
either an ABI 373 or 377 automated sequencer with fluo-
rescent dye terminator chemistry (Applied Biosystems).
The PCR products were also digested with Pvu II and
Msp I in order to screen for the C598T and C2836T
SNPs, respectively.
Abbreviations
DAPC: Dystrophin-associated protein complex; DMN:
Desmuslin, SNP: Single-nucleotide polymorphism; IF:
Intermediate filament
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